4-(2-bromo-5-fluorophenoxy)-1-[5-(2H-tetrazol-5-yl)-1,3,4-thiadiazol-2-yl]piperidine | 1030613-20-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-(2-bromo-5-fluorophenoxy)-1-[5-(2H-tetrazol-5-yl)-1,3,4-thiadiazol-2-yl]piperidine
• 英文别名: 4-(2-bromo-5-fluorophenoxy)-1-[5-(2H-tetrazol-5-yl)-[1,3,4]-thiadiazol-2-yl]piperidine；2-[4-(2-bromo-5-fluorophenoxy)piperidin-1-yl]-5-(2H-tetrazol-5-yl)-1,3,4-thiadiazole
• CAS: 1030613-20-7
• 化学式: C₁₄H₁₃BrFN₇OS
• 分子量: 426.272
• InChiKey: VJYMDTMHJYNRJZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  121
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  4-(2-bromo-5-fluorophenoxy)-1-[5-(2H-tetrazol-5-yl)-1,3,4-thiadiazol-2-yl]piperidine 在 sodium hydride 、 sodium hydroxide 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 0.08h， 生成 5-[5-[4-(2-溴-5-氟苯氧基)-1-哌啶基]-1,3,4-噻二唑-2-基]-2H-四唑-2-乙酸
  参考文献：
  名称：

  Development of a Liver-Targeted Stearoyl-CoA Desaturase (SCD) Inhibitor (MK-8245) to Establish a Therapeutic Window for the Treatment of Diabetes and Dyslipidemia

  摘要：

  The potential use of SCD inhibitors for the chronic treatment of diabetes and dyslipidemia has been limited by preclinical adverse events associated with inhibition of SCD in skin and eye tissues. To establish a therapeutic window, we embarked on designing liver-targeted SCD inhibitors by utilizing molecular recognition by liver-specific organic anion transporting polypeptides (OATPs). In doing so, we set out to target the SCD inhibitor to the organ believed to be responsible for the therapeutic efficacy (liver) while minimizing its exposure in the tissues associated with mechanism-based SCD depletion of essential lubricating lipids (skin and eye). These efforts led to the discovery of MK-8245 (7), a potent, liver-targeted SCD inhibitor with preclinical antidiabetic and antidyslipidemic efficacy with a significantly improved therapeutic window.

  DOI：

  10.1021/jm200319u
• 作为产物：
  描述：

  2-溴-5-氟苯酚 在 sodium azide 、 偶氮二甲酸二叔丁酯 、 吡啶盐酸盐 、 N,N-二异丙基乙胺 、 三苯基膦 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 N-甲基吡咯烷酮 、 二氯甲烷 为溶剂， 反应 29.0h， 生成 4-(2-bromo-5-fluorophenoxy)-1-[5-(2H-tetrazol-5-yl)-1,3,4-thiadiazol-2-yl]piperidine
  参考文献：
  名称：

  Development of a Liver-Targeted Stearoyl-CoA Desaturase (SCD) Inhibitor (MK-8245) to Establish a Therapeutic Window for the Treatment of Diabetes and Dyslipidemia

  摘要：

  The potential use of SCD inhibitors for the chronic treatment of diabetes and dyslipidemia has been limited by preclinical adverse events associated with inhibition of SCD in skin and eye tissues. To establish a therapeutic window, we embarked on designing liver-targeted SCD inhibitors by utilizing molecular recognition by liver-specific organic anion transporting polypeptides (OATPs). In doing so, we set out to target the SCD inhibitor to the organ believed to be responsible for the therapeutic efficacy (liver) while minimizing its exposure in the tissues associated with mechanism-based SCD depletion of essential lubricating lipids (skin and eye). These efforts led to the discovery of MK-8245 (7), a potent, liver-targeted SCD inhibitor with preclinical antidiabetic and antidyslipidemic efficacy with a significantly improved therapeutic window.

  DOI：

  10.1021/jm200319u
• 作为试剂：
  描述：

  5-[4-(2-溴-5-氟苯氧基)哌啶-1-基]-1,3,4-噻二唑-2-甲腈 、 叠氮化钠 、 Hydron;pyridin-1-ium;chloride 、 MeOH Et2O heptane 在 4-(2-bromo-5-fluorophenoxy)-1-[5-(2H-tetrazol-5-yl)-1,3,4-thiadiazol-2-yl]piperidine 作用下， 以 N-甲基吡咯烷酮 为溶剂， 生成 4-(2-bromo-5-fluorophenoxy)-1-[5-(2H-tetrazol-5-yl)-1,3,4-thiadiazol-2-yl]piperidine
  参考文献：
  名称：

  Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase

  摘要：

  结构式I的Azacycloalkane衍生物是选择性抑制stearoyl-coenzyme A delta-9 desaturase (SCD1)相对于其他已知的stearoyl-coenzyme A desaturases的化合物。本发明的化合物可用于预防和治疗与异常脂质合成和代谢相关的疾病，包括心血管疾病，如动脉硬化; 肥胖症; 糖尿病; 神经系统疾病; 代谢综合征; 胰岛素抵抗和肝脂肪变性。

  公开号：

  US20080132542A1

文献信息

• AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE
  申请人：Merck Canada Inc.

  公开号：EP2099793B1

  公开（公告）日：2012-02-01
• US8063224B2
  申请人：——

  公开号：US8063224B2

  公开（公告）日：2011-11-22
• [EN] AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE<br/>[FR] DÉRIVÉS D'AZACYCLOALKANE UTILISÉS COMME INHIBITEURS DE LA COENZYME A DELTA-9 DÉSATURASE-STEAROYLE
  申请人：MERCK FROSST CANADA LTD

  公开号：WO2008064474A1

  公开（公告）日：2008-06-05

  [EN] Azacycloalkane derivatives of structural formula I are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; and liver steatosis.
  [FR] L'invention porte sur des dérivés d'azacycloalkane de la formule structurelle I qui sont des inhibiteurs sélectifs de la coenzyme A delta-9 désaturase- stearoyle (SCD1) par rapport aux autres coenzymes A désaturases-stearoyles connues. Les composés de l'invention sont utilisés pour prévenir et traiter les états liés à une synthèse et un métabolisme anormaux des lipides, y compris la maladie cardiovasculaire, par exemple l'athérosclérose, l'obésité, le diabète, la maladie neurologique, le syndrome métabolique, la résistance à l'insuline et la stéatose hépatique.